Association of EGFR c.2073A > T polymorphism with decreased risk of diffusely infiltrating astrocytoma in a Brazilian case-control study

Autor(es):Mostrar menos -

Barbosa, K. C. ^[1] ; Oba-Shinjo, S. M. ^[1] ; Uno, M. ^[1] ; Carvalho, Po. ^[1] ; Rosemberg, S. ^[2] ; Aguiar, Ph. P. ^[1] ; Carlotti, C. G. ^[3] ; Malheiros, S. M. F. ^[4] ; Toledos, S. ^[5] ; Lotufo, P. ^[6] ; Marie, S. K. N. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Med, Dept Neurol, BR-01246903 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Sch Med, Dept Pathol, BR-01246903 Sao Paulo - Brazil

^[3] Univ Sao Paulo, Sch Med Ribeirao Preto, Div Neurosurg, Dept Surg, BR-14049 Ribeirao Preto - Brazil

^[4] Univ Fed Sao Paulo, Dept Neurol, Sao Paulo - Brazil

^[5] Univ Fed Sao Paulo, Pediat Oncol Inst, Dept Pediat, Sao Paulo - Brazil

^[6] Univ Sao Paulo, Hosp Univ Sao Paulo, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: International Journal of Biological Markers; v. 23, n. 3, p. 140-146, JUL-SEP 2008.
• Citações Web of Science: 5

Resumo

Epidermal growth factor receptor (EGFR) gene overexpression has been implicated in the development of many types of tumors, including glioblastomas, the most frequent diffusely infiltrating astrocytomas. However, little is known about the influence of the polymorphisms of EGFR on EGFR production and/or activity, possibly modulating the susceptibility to astrocytomas. This study aimed to examine the association of two EGFR promoter polymorphisms (c.-191C > A and c.-216G > T) and the c.2073A > T polymorphism located in exon 16 with susceptibility to astrocytomas, EGFR gene expression and survival in a case-control study of 193 astrocytoma patients and 200 cancer-free controls. We found that the variant TT genotype of the EGFR c.2073A > T polymorphism was associated with a significantly decreased risk of astrocytoma when compared with the AA genotype {[}sex- and age-adjusted odds ratio 0.51, 95% confidence interval 0.26-0.98]. No association of the two promoter EGFR polymorphisms (or combinations of these polymorphisms) and risk of astrocytomas, EGFR expression or survival was found. Our findings suggest that modulation of the EGFR c.2073A > T polymorphism could play a role in future therapeutic approaches to astrocytoma. (Int J Biol Markers 2008; 23: 140-6) (AU)

• Processo FAPESP: 04/12133-6 - Procura de marcadores moleculares relacionados ao diagnóstico e prognóstico de tumores do sistema nervoso central
• Beneficiário: Suely Kazue Nagahashi Marie
• Modalidade de apoio: Auxílio à Pesquisa - Temático